Clinicopathological Features and Mortality in Patients With Kaposi Sarcoma and HIV : A Retrospective Analysis of a Thirty-Year Study From a Peruvian Oncologic Center
PURPOSE: Kaposi's sarcoma (KS) is a multifocal angioproliferative disease. In Peru, the implementation of the highly active antiretroviral treatment (HAART) program was in 2005, the model for treating patients with HIV-positive KS shifted to a potential cure. In this study, we aim to compare clinicopathological characteristics and prognostic factors associated with outcomes in patients with HIV-positive KS.
METHODS: We developed a retrospective cohort study that includes patients with HIV/AIDS and KS seen in the Instituto Nacional de Enfermedades Neoplasicas between 1987 and 2017. Patients were divided into two groups according to the implementation of HAART in our country: the non-HAART group and those treated with HAART after 2005. Multivariate analysis for overall survival (OS) was performed with the Cox proportional hazard regression model.
RESULTS: There was a greater visceral compromise and more extensive oral cavity involvement in the non-HAART group (60% 31.7%, P < .01). Regarding the immune status, there was a significant difference from the CD4 count at 1-year follow-up (73 v 335, P = .01). The CD4/CD8 rate were significant different before QT (0.23 v 0.13, P = .01) and at 1-year follow-up (0.12 v 0.32, P = .03.). The estimated 5-year OS rate was significantly lower (P = .0001) for the non-HAART group (41.7%; 95% CI, 25.9 to 56.9) compared with the HAART group (79.3%; 95% CI, 66.8 to 87.5). In the multivariate model for OS, full-HAART regimen and previous diagnosis of HIV/AIDS (P < .01) were significantly associated with longer survival.
CONCLUSION: Clinical and demographic characteristics of our patients are compatible with the literature, but we report a higher rate of gastrointestinal involvement. Furthermore, our findings provide evidence for the importance of HAART and its ability to reduce KS-related mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
JCO global oncology - 8(2022) vom: 12. Juni, Seite e2100379 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cuellar, Luis E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.06.2022 Date Revised 03.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1200/GO.21.00379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342492098 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342492098 | ||
| 003 | DE-627 | ||
| 005 | 20231226014235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/GO.21.00379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342492098 | ||
| 035 | |a (NLM)35728013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cuellar, Luis E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinicopathological Features and Mortality in Patients With Kaposi Sarcoma and HIV |b A Retrospective Analysis of a Thirty-Year Study From a Peruvian Oncologic Center |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2022 | ||
| 500 | |a Date Revised 03.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Kaposi's sarcoma (KS) is a multifocal angioproliferative disease. In Peru, the implementation of the highly active antiretroviral treatment (HAART) program was in 2005, the model for treating patients with HIV-positive KS shifted to a potential cure. In this study, we aim to compare clinicopathological characteristics and prognostic factors associated with outcomes in patients with HIV-positive KS | ||
| 520 | |a METHODS: We developed a retrospective cohort study that includes patients with HIV/AIDS and KS seen in the Instituto Nacional de Enfermedades Neoplasicas between 1987 and 2017. Patients were divided into two groups according to the implementation of HAART in our country: the non-HAART group and those treated with HAART after 2005. Multivariate analysis for overall survival (OS) was performed with the Cox proportional hazard regression model | ||
| 520 | |a RESULTS: There was a greater visceral compromise and more extensive oral cavity involvement in the non-HAART group (60% 31.7%, P < .01). Regarding the immune status, there was a significant difference from the CD4 count at 1-year follow-up (73 v 335, P = .01). The CD4/CD8 rate were significant different before QT (0.23 v 0.13, P = .01) and at 1-year follow-up (0.12 v 0.32, P = .03.). The estimated 5-year OS rate was significantly lower (P = .0001) for the non-HAART group (41.7%; 95% CI, 25.9 to 56.9) compared with the HAART group (79.3%; 95% CI, 66.8 to 87.5). In the multivariate model for OS, full-HAART regimen and previous diagnosis of HIV/AIDS (P < .01) were significantly associated with longer survival | ||
| 520 | |a CONCLUSION: Clinical and demographic characteristics of our patients are compatible with the literature, but we report a higher rate of gastrointestinal involvement. Furthermore, our findings provide evidence for the importance of HAART and its ability to reduce KS-related mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Meza, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Holguín, Alexis Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Velarde, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Portillo-Alvarez, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Sulca-Huamani, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Intimayta-Escalante, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Gaby-Pérez, Rushmely |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Arpan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO global oncology |d 2020 |g 8(2022) vom: 12. Juni, Seite e2100379 |w (DE-627)NLM30617877X |x 2687-8941 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g day:12 |g month:06 |g pages:e2100379 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/GO.21.00379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |b 12 |c 06 |h e2100379 | ||